ME Therapeutics Holdings Inc.
METXF
$2.95
$0.000.09%
OTC PK
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 533.10K | 528.90K | 561.00K | 612.50K | 783.60K |
| Depreciation & Amortization | 77.40K | 71.00K | 59.60K | 40.20K | 21.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.07M | 965.70K | 916.70K | 861.40K | 999.10K |
| Operating Income | -1.07M | -965.70K | -916.70K | -861.40K | -999.10K |
| Income Before Tax | -964.10K | -891.70K | -856.90K | -838.10K | -950.70K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.96 | -0.89 | -0.86 | -0.84 | -0.95 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -964.10K | -891.70K | -856.90K | -838.10K | -950.70K |
| EBIT | -1.07M | -965.70K | -916.70K | -861.40K | -999.10K |
| EBITDA | -1.03M | -925.30K | -877.50K | -831.10K | -977.00K |
| EPS Basic | -0.03 | -0.03 | -0.03 | -0.03 | -0.04 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | -0.03 | -0.03 | -0.03 | -0.03 | -0.04 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 119.04M | 115.82M | 111.22M | 106.81M | 102.31M |
| Average Diluted Shares Outstanding | 119.04M | 115.82M | 111.22M | 106.81M | 102.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |